Chief executives of small-to-medium biotech companies remain confident about their ability to bring drugs to market, but worries about capital and the deal-making landscape remain.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho
